CNSX:VPH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Valeo Pharma Inc. acquires and markets specialty products in the United States and Canada.


Snowflake Analysis

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has Valeo Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VPH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

61.6%

VPH

-1.4%

CA Healthcare

0.8%

CA Market


1 Year Return

82.9%

VPH

-27.1%

CA Healthcare

-11.3%

CA Market

Return vs Industry: VPH exceeded the Canadian Healthcare industry which returned -27.1% over the past year.

Return vs Market: VPH exceeded the Canadian Market which returned -11.1% over the past year.


Shareholder returns

VPHIndustryMarket
7 Day61.6%-1.4%0.8%
30 Day215.9%2.1%3.0%
90 Day396.4%14.1%9.0%
1 Year82.9%82.9%-24.6%-27.1%-8.2%-11.3%
3 Yearn/a-26.3%-36.6%4.1%-5.8%
5 Yearn/a-32.1%-47.2%21.5%3.1%

Price Volatility Vs. Market

How volatile is Valeo Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Valeo Pharma undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Valeo Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Valeo Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VPH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Valeo Pharma regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Valeo Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Valeo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Valeo Pharma performed over the past 5 years?

-17.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VPH is currently unprofitable.

Growing Profit Margin: VPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VPH is unprofitable, and losses have increased over the past 5 years at a rate of -17.2% per year.

Accelerating Growth: Unable to compare VPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VPH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (4.8%).


Return on Equity

High ROE: VPH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Valeo Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: VPH has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VPH has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VPH has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VPH's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VPH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VPH has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26% each year


Next Steps

Dividend

What is Valeo Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VPH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VPH's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average board tenure


CEO

Steve Saviuk (61yo)

17.5yrs

Tenure

CA$238,053

Compensation

Mr. Steven Saviuk, also known as Steve, CA, has been Non-Independent Director of Ortho Regenerative Technologies Inc. since February 5, 2015. He had been Executive Chairman of the Board of Directors at Ort ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD175.08K) is about average for companies of similar size in the Canadian market ($USD175.28K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Steven Saviuk
President17.5yrsCA$238.05k0.20% CA$160.9k
Richard MacKay
Chairmanno datano data14.24% CA$11.2m
Michel Trudeau
Independent Director0.83yrno data0.35% CA$278.0k
Michael Wells
Independent Director1.67yrsno datano data
Vincent Hogue
Independent Director2yrsno data0.45% CA$350.8k
Maureen Brennan
Independent Director1.67yrsno datano data

1.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: VPH's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VPH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.9%.


Top Shareholders

Company Information

Valeo Pharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Valeo Pharma Inc.
  • Ticker: VPH
  • Exchange: CNSX
  • Founded: 2003
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: CA$78.757m
  • Shares outstanding: 56.66m
  • Website: https://www.valeopharma.com

Number of Employees


Location

  • Valeo Pharma Inc.
  • 16667 Hymus Boulevard
  • Kirkland
  • Quebec
  • H9H 4R9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VPHCNSX (Canadian National Stock Exchange)YesClass A SharesCACADFeb 2019

Biography

Valeo Pharma Inc. acquires and markets specialty products in the United States and Canada. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; and M-Eslon, an extended release morphine sulphate used for pain management. The company also offers Ondansetron ODT for prevention of nausea and vomiting caused by cancer chemotherapy; Benztropine, an anticholinergic agent used for the treatment of Parkinson’s disease; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson’s disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/12 00:21
End of Day Share Price2020/07/10 00:00
Earnings2020/04/30
Annual Earnings2019/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.